Prophylactic perioperative cefuroxime levels in plasma and adipose tissue at the time of caesarean section (C-LACE) : a protocol for a pilot experimental, prospective study with non-probability sampling to determine interpatient variability

Alrammaal, Hanadi H. and Batchelor, Hannah K. and Chong, Hsu P. and Hodgetts Morton, Victoria and Morris, R. Katie (2021) Prophylactic perioperative cefuroxime levels in plasma and adipose tissue at the time of caesarean section (C-LACE) : a protocol for a pilot experimental, prospective study with non-probability sampling to determine interpatient variability. Pilot and Feasibility Studies, 7. 54. ISSN 2055-5784

[thumbnail of Alrammaal-etal-PFS-2021-Prophylactic-perioperative-cefuroxime-levels-in-plasma]
Preview
Text (Alrammaal-etal-PFS-2021-Prophylactic-perioperative-cefuroxime-levels-in-plasma)
Alrammaal_etal_PFS_2021_Prophylactic_perioperative_cefuroxime_levels_in_plasma.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (544kB)| Preview

    Abstract

    Background: The aim of the C-LACE study is to measure cefuroxime concentration in plasma and adipose tissue of non-obese and obese pregnant women undergoing caesarean section. Methods: This study plans to compare maternal cefuroxime concentrations (plasma and adipose tissue), at the time of skin incision and time of skin closure during a caesarean section from non-obese (body mass index BMI < 30 kg/m2) and obese (BMI ≥ 30 kg/m2) pregnant women. The incidence of post-surgical site infection will also be measured. At least 15 participants are required for each arm (non-obese vs obese) with a total of 30 participants. The study participants will be followed up between 30 and 40 days post-caesarean section to record details of any post-caesarean surgical infection to explore correlations between BMI, measured cefuroxime concentrations and post-caesarean infection rates. Discussion: This pilot study will allow the development of a model testing the inter-patient variability in plasma and adipose tissue concentrations of cefuroxime. The results will facilitate the development of a larger study to determine whether differences in cefuroxime plasma and tissue concentration in obese and non-obese women can support the development of a physiologically based pharmacokinetic model. This model can then be used to propose dosing adjustments that can be used in a further trial to optimise cefuroxime dosing for women undergoing caesarean section. Trial registration: ISRCTN Registry, ISRCTN17527512. Registered on 26 October 2020

    ORCID iDs

    Alrammaal, Hanadi H., Batchelor, Hannah K. ORCID logoORCID: https://orcid.org/0000-0002-8729-9951, Chong, Hsu P., Hodgetts Morton, Victoria and Morris, R. Katie;